A 41-year-old woman with menorrhagia, anemia, and fibroids: Review of treatment of uterine fibroids

JAMA

Volumn 301, Issue 1, 2009, Pages 82-93

  Van Voorhis, Bradley ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANEMIA; CASE REPORT; CESAREAN SECTION; CLINICAL FEATURE; DIAGNOSTIC IMAGING; FEMALE; HEMATOCRIT; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; LAPAROTOMY; MENORRHAGIA; MYOMECTOMY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SEXUAL BEHAVIOR; THERAPEUTIC ABORTION; UTERUS MYOMA; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; ENDOMETRIUM ABLATION; FATIGUE; HYSTERECTOMY; LEIOMYOMA; ULTRASOUND THERAPY; UTERINE ARTERY EMBOLIZATION; UTERUS CANCER;

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GESTAGEN;

ADULT; ANEMIA; ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL ABLATION TECHNIQUES; FATIGUE; FEMALE; HUMANS; HYSTERECTOMY; LEIOMYOMA; MENORRHAGIA; PROGESTINS; ULTRASONIC THERAPY; UTERINE ARTERY EMBOLIZATION; UTERINE NEOPLASMS;

EID: 58149401852     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.791     Document Type: Review

References (93)

1. Hodge JC, Morton CC. Genetic heterogeneity among uterine leiomyomata: insights into malignant progression. Hum Mol Genet. 2007;16:R7-R13.
2. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100-107.
3. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine leiomyomas. Am J Obstet Gynecol. 1995;172(1 pt 1):14-18.
4. Brandon DD, Erickson TE, Keenan EJ, et al. Estrogen receptor gene expression in human uterine leiomyomas. J Clin Endocrinol Metab. 1995;80(6):1876-1881.
5. Sumitani H, Shozu M, Segawa T, et al. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/paracrine mechanism. Endocrinology. 2000;141(10):3852-3861.
6. Schwartz SM, Marshall LM, Baird DD. Epidemiologic contributions to understanding the etiology of uterine leiomyomata. Environ Health Perspect. 2000;108(suppl 5):821-827.
7. Wise LA, Palmer JR, Harlow BL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol. 2004;159(2):113-123.
8. Lumbiganon P, Rugpao S, Phandhu-fung S, Laopaiboon M, Vudhikamraksa N, Werawatakul Y. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicenter case-control study. Br J Obstet Gynaecol. 1996;103(9):909-914.
9. Orsini G, Laricchia L, Fanell M. Low-dose combination oral contraceptive use in women with uterine leiomyomas. Minerva Ginecol. 2002;54(3):253-261.
10. Van Voorhis BJ, Romitti PA, Jones MP. Family history as a risk factor for development of uterine leiomyomas: results of a pilot study. J Reprod Med. 2002;47(8):663-669.
11. Vikhlyaeva EM, Khodzhaeva ZS, Fantschenko ND. Familial predisposition to uterine leiomyomas. Int J Gynaecol Obstet. 1995;51(2):127-131.
12. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90(6):967-973.
13. Wegienka G, Baird DD, Hertz-Picciotto I, et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol. 2003;101(3):431-437.
14. Marino JL, Eskenazi B, Warner M, Samuels S, Vercellini P, Gavoni N, Olive D. Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. Hum Reprod. 2004;19(10):2350-2355.
15. Halberg L, Högdahl AM, Nilson L, Rybo G. Menstrual blood loss - a population study: variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966;45(3):320-351.
16. Haynes PJ, Hodgson H, Anderson A, Turnbull A. Measurement of menstrual blood loss in patients complaining of menorrhagia. Br J Obstet Gynaecol. 1977;84(10):763-768.
17. Warner PE, Critchley H, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol. 2004;190(5):1216-1223.
18. Clevenger-Hoeft M, Syrop CH, Stovall DW, Van Voorhis BJ. Sonohysterography in premenopausal women with and without abnormal bleeding. Obstet Gynecol. 1999;94(4):516-520.
19. Van Voorhis BJ, Santoro N, Harlow S, Crawford SL, Randolph J. The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause. Obstet Gynecol. 2008;112(1):101-108.
20. Stovall DW. Clinical symptomatology of uterine leiomyomas. Clin Obstet Gynecol. 2001;44(2):364-371.
21. Lippman SA, Warner M, Samuels S, Olive D, Vercellini P, Eskenazi B. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril. 2003;80(6):1488-1494.
22. The Practice Committee of the American Society for Reproductive Medicine. Myomas and reproductive function. Fertil Steril. 2004;82(suppl 1):S111-S116.
23. Emanuel MH, Verdel MJ, Wamsteker K, Lammes FB. A prospective comparison of transvaginal ultrasonography and diagnostic hysteroscopy in the evaluation of patients with abnormal uterine bleeding: clinical implications. Am J Obstet Gynecol. 1995;172(2 pt 1):547-552.
24. Derman SG, Rehnstrom J, Neuwirth RS. The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol. 1991;77(4):591-594.
25. Tjarks M, Van Voorhis BJ. Treatment of endometrial polyps. Obstet Gynecol. 2000;96(6):886-889.
26. Di Spiezio Sardo A, Mazzoni I, Bramante S, et al. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. Hum Reprod Update. 2008;14(2):101-119.
27. Management of Anovulatory Bleeding: ACOG 2008 Compendium of Selected Publications Vol II: Practice Bulletins. March 2000(14):1049-1056. Clinical Management Guidelines for Obstetrician-Gynecologists.
28. Seracchioli R, Rossi S, Govoni F, et al. Fertility and obstetric outcome after laparoscopic myomectomy of large myomata: a randomized comparison with abdominal myomectomy. Hum Reprod. 2000;15(12):2663-2668.
29. Dubuisson JB, Chapron C, Levy L. Difficulties and complications of laparoscopic myomectomy. J Gynecol Surg. 1996;12(3):159-165.
30. Iverson RE Jr, Chelmow D, Strohbehn K, Waldman L, Evantash EG. Relative morbidity of abdominal hysterectomy and myomectomy for management of uterine leiomyomas. Obstet Gynecol. 1996;88(3):415-419.
31. Celik H, Sapmaz E. Use of a single preoperative dose of misoprostol is efficacious for patients who undergo abdominal myomectomy. Fertil Steril. 2003;79(5):1207-1210.
32. Olufowobi O, Sharif K, Papaionnou S, Neelakantan D, Mohammed H, Afnan M. Are the anticipated benefits of myomectomy achieved in women of reproductive age: a 5-year review of the results at the UK tertiary hospital. J Obstet Gynaecol. 2004;24(4):434-440.
33. LaMorte AI, Lalwani S, Diamond MP. Morbidity associated with abdominal myomectomy. Obstet Gynecol. 1993;82(6):897-900.
34. Frederick J, Hardie M, Reid M, Fletcher H, Wynter S, Frederick C. Operative morbidity and reproductive outcome in secondary myomectomy: a prospective cohort study. Hum Reprod. 2002;17(11):2967-2971.
35. Myers ER, Barber MD, Gustilo-Ashby T, Couchman G, Matchar DBB, McGrory DC. Management of uterine leiomyomata: what do we really know? Obstet Gynecol. 2002;100(1):8-17.
36. Griffiths A, D'Angelo A, Amso N. Surgical treatment of fibroids for subfertility. Cochrane Database Syst Rev. 2006;3(issue 3):CD003857.
37. Fedele L, Parazzini F, Luchini L, Mezzopane R, Tozzi L, Villa L. Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Hum Reprod. 1995;10(7):1795-1796.
38. Malone LJ. Myomectomy: recurrence after removal of solitary and multiple myomas. Obstet Gynecol. 1969;34(2):200-203.
39. Fedele L, Vercellini P, Bianchi S, Brioschi D, Dorta M. Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence. Br J Obstet Gynaecol. 1990;97(5):393-396.
40. Nezhat FR, Roemisch M, Nezhat CH, Seidman DS, Nezhat CR. Recurrence rate after laparoscopic myomectomy. J Am Assoc Gynecol Laparosc. 1998;5(3):237-240.
41. Merrill RM. Hysterectomy surveillance in the United States, 1997 through 2005. Med Sci Monit. 2008;14(1):CR24-CR31.
42. Falcone T, Walters MD. Hysterectomy for benign disease. Obstet Gynecol. 2008;111(3):753-767.
43. Garry R, Fountain J, Mason S, et al. The Evaluate Study: two parallel randomised trials, one comparing laparoscopic with abdominal hysterectomy, the other comparing laparoscopic with vaginal hysterectomy [published correction appears in BMJ. 2004;328:494]. BMJ. 2004;328(7432):129-136.
44. Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women's Health Study, I: outcomes of hysterectomy. Obstet Gynecol. 1994;83(4):556-565.
45. Kjerulff KH, Langenberg PW, Rhodes JC, Harvey LA, Guzinski BM, Stolley PD. Effectiveness of hysterectomy. Obstet Gynecol. 2000;95(3):319-326.
46. Weber AM, Walters MD, Schover LR, Church JM, et al. Functional outcomes and satisfaction after abdominal hysterectomy. Am J Obstet Gynecol. 1999;181(3):530-535.
47. Hartmann KE, Ma C, Lamvu GM, Langenberg PW, Steege JF, Kjerulff KH. Quality of life and sexual function after hysterectomy in women with preoperative pain and depression. Obstet Gynecol. 2004;104(4):701-709.
48. Dutton S, Hirst A, McPherson K, Nicholson T, Maresh MA. UK multicentre retrospective cohort study comparing hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids (HOPEFUL Study): main results on medium-term safety and efficacy. BJOG. 2007;114(11):1340-1351.
49. Farquhar CM, Sadler L, Harvey SA, Stewart AW. The association of hysterectomy and menopause: a prospective cohort study. BJOG. 2005;112(7):956-962.
50. Magos A. Does hysterectomy cause urinary incontinence? Lancet. 2007;370(9597):1462-1463.
51. Altman D, Granath F, Cnattingius S, Falconer C. Hysterectomy and risk of stress urinary-incontinence surgery: nationwide cohort study. Lancet. 2007;370(9597):1494-1499.
52. Dällenbach P, Kaelin-Gambirasio I, Dubuisson JB, Boulvain M. Risk factors for pelvic organ prolapse repair after hysterectomy. Obstet Gynecol. 2007;110(3):625-632.
53. Edwards RD, Moss JG, Lumsden MA, et al; Committee of the Randomized Trial of Embolization versus Surgical Treatment for Fibroids. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med. 2007;356(4):360-370.
54. Volkers NA, Hehenkamp WJK, Birnie E, et al. Uterine artery embolization in the treatment of symptomatic uterine fibroid tumors (EMMY Trial): periprocedural results and complications. J Vasc Interv Radiol. 2006;17(3):471-480.
55. Goodwin SC, Spies JB, Worthington-Kirsch R, et al; Fibroid Registry for Outcomes Data (FIBROID) Registry Steering Committee and Core Site Investigators. Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol. 2008;111(1):22-33.
56. Gabriel-Cox K, Jacobson GF, Armstrong MA, Huang YY, Learman LA. Predictors of hysterectomy after uterine artery embolization for leiomyoma. Am J Obstet Gynecol. 2007;196(6):588.e1-588.e6.
57. Hehenkamp WJK, Volkers NA, Birnie E, Reekers JA, Ankum WM. Symptomatic uterine fibroids: treatment with uterine artery embolization or hysterectomy - results from the randomized clinical Embolisation versus Hysterectomy (EMMY) trial. Radiology. 2008;246(3):823-832.
58. Pinto I, Chimeno P, Romo A, et al. Uterine fibroids: uterine artery embolization versus abdominal hysterectomy for treatment - a prospective, randomized, and controlled clinical trial. Radiology. 2003;226(2):425-431.
59. Hehenkamp WJK, Volkers NA, Broekmans FJM, et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod. 2007;22(7):1996-2005.
60. Mara M, Maskova J, Fucikova Z, Kuzel D, Belsan T, Sosna O. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol. 2008;31(1):73-85.
61. Holub Z, Mara M, Kuzel D, Jabor A, Maskova J, Eim J. Pregnancy outcomes after uterine artery occlusion: prospective multicentric study. Fertil Steril. 2008;90(5):1886-1891.
62. Walker WJ, McDowell SJ. Pregnancy after uterine artery embolization of leiomyomata: a series of 56 completed pregnancies. Am J Obstet Gynecol. 2006;195(5):1266-1271.
63. Pron G, Mocarski E, Bennett J, Vilos G, Common A, Vanderburgh L; Ontario UFE Collaborative Group. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Obstet Gynecol. 2005;105(1):67-76.
64. Goldberg J, Pereira L. Pregnancy outcomes following treatment for fibroids: uterine fibroid embolization versus laparoscopic myomectomy. Curr Opin Obstet Gynecol. 2006;18(4):402-406.
65. Sharp HT. Assessment of new technology in the treatment of idiopathic menorrhagia and uterine leiomyomata. Obstet Gynecol. 2006;108(4):990- 1003.
66. Mall A, Shirk G, Van Voorhis BJ. Previous tubal ligation is a risk factor for hysterectomy after rollerball endometrial ablation. Obstet Gynecol. 2002;100(4):659-664.
67. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol. 1991;31(1):66-70.
68. Iyer V, Farquhar C, Jepson R. Oral contraceptive pills for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;(2):CD000154.
69. Mäkäräinen L, Hlikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol. 1986;93(9):974-978.
70. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev. 2008;(1):CD001016.
71. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005;(4):CD002126.
72. Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomized trial. Lancet. 2001;357(9252):273-277.
73. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia. JAMA. 2004;291(12):1456-1463.
74. Mercorio F, De Simone R, Di Spiezio Sardo A, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of a myoma-related menorrhagia. Contraception. 2003;67(4):277-280.
75. Rosa e Silva JC, de Sá Rosa e Silva AC, Cândido dos Reis FJ, et al. Use of a levonorgestrel-releasing intrauterine device for the symptomatic treatment of uterine myomas. J Reprod Med. 2005;50(8):613-617.
76. Jindabanjerd K, Taneepanichskul S. The use of levonorgestrel IUD in the treatment of uterine myoma in Thai women. J Med Assoc Thai. 2006;89(4)(suppl 4):S147-S151.
77. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest. 2005;59(1):29-35.
78. Learman LA, Summitt RL Jr, Varner RE, et al; Medicine or Surgery Research Group. Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial. Obstet Gynecol. 2004;103(5 pt 1):824-833.
79. DeWaay DJ, Syrop CH, Nygaard IE, Davis WA, Van Voorhis BJ. Natural history of uterine polyps and leiomyomata. Obstet Gynecol. 2002;100(1):3-7.
80. Parker WA, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyomata and rapidly growing leiomyoma. Obstet Gynecol. 1994;84:414-418.
81. Lethaby AE, Vollenhoven BJ. An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(2):307-331.
82. Palomba S, Affinito P, Giovanni MD, et al. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril. 1998;70(1):111-118.
83. Wu T, Chen X, Xie L. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev. 2007;(4):CD005287.
84. Varelas FK, Papanicolaou AN, Vavatsi-Christaki N, Makedos GA, Vlassis GD. The effect of anastrozole on symptomatic uterine leiomyomata. Obstet Gynecol. 2007;110(3):643-649.
85. Hilário SG, Bozzini N, Borsari R, Baracat EC. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertil Steril. In press.
86. Bulun SE, Lin Z, Imir G, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev. 2005;57(3):359-383.
87. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101(2):243-250.
88. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size. Obstet Gynecol. 2006;108(6):1381-1387.
89. Stewart EA, Gostout B, Rabinovici J, Kim HS, Regan L, Tempany CM. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol. 2007;110(2 Pt 1):279-287.
90. Hesley GK, Felmlee P, Gebhart JB, et al. Noninvasive treatment of uterine fibroids: early Mayo Clinic experience with magnetic resonance imaging - guided focused ultrasound. Mayo Clin Proc. 2006;81(7):936-942.
91. Stewart EA, Rabinovici J, Tempany CMC, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids [published correction appears in Fertil Steril. 2006;85(4):1072]. Fertil Steril. 2006;85(1):22-29.
92. Yang CH, Lee JN, Hsu SC, Kuo CH, Tsai EA. Effect of hormone replacement therapy on uterine fibroids in post-menopausal women - a 3-year study. Maturitas. 2002;43(1):35-39.
93. Somigliana E, Vercellini P, Daguati R, Pasin R, De Giorgi O, Crosignani PG. Fibroids and female reproduction: a critical analysis of the evidence. Hum Reprod Update. 2007;13(5):465-476.